Figure 2From: VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Survival analysis in patients treated with FLO versus FLP in relation to the expression of VEGFR-3. A. VEGFR-3 negative in observation time of 5Â years. B. VEGFR-3 positive in observation time of 60Â months.Back to article page